SCHEMBL4110381

SCHEMBL4110381

CCOc1ccc(NC(=O)Nc2cccc(C(C)=O)c2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.82
RAB9A P51151 5/20 0.82
SMN1; SMN2 Q16637 4/20 0.82
MITF O75030 1/20 0.82
PAX8 Q06710 1/20 0.82
KMT2A Q03164 10/20 0.79
MEN1 O00255 9/20 0.79
MAPT P10636 8/20 0.79
ALDH1A1 P00352 5/20 0.67
MAPK1 P28482 3/20 0.66
LMNA P02545 3/20 0.66
PKM P14618 2/20 0.65
USP2 O75604 1/20 0.65
TP53 P04637 1/20 0.65
TSHR P16473 1/20 0.65
MCL1 Q07820 1/20 0.65
NOX1 Q9Y5S8 1/20 0.65
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4105865 0.89 RAB9A (0.67) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL4118118 0.89 MAPT (0.83) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL4128090 0.88 MAPT (1.00) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL4106982 0.88 KMT2A (0.66) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL4111978 0.87 NPC1 (0.75) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL4105152 0.87 MAPT (0.77) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL4121731 0.84 MAPT (0.72) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL4104467 0.84 MAPT (0.76) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL4112399 0.83 MEN1 (0.76) NPC1RAB9ASMN1; SMN2MITFPAX8
SCHEMBL10576308 0.83 MAPT (0.86) NPC1RAB9ASMN1; SMN2MITFPAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 NPC1 927/4885RAB9A 815/4885SMN1; SMN2 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.